4
Changes in Ownership
GYRE THERAPEUTICS, INC. Filed Acc 0001140361-24-024125
Director sold 20,000 shares at an average $14.13 ($282,577)
- Director acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
USMAN NASSIM · Director
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-05-01 | Exercise or conversion : show line 1 in the form 10b5-1 | +20,000 | $6.93 | $138,600 | 21,636 | D |
| 2024-05-01 | Sale : show line 2 in the form 10b5-1 | −14,900 | $13.86 | $206,514 | 6,736 | D |
| 2024-05-01 | Sale : show line 3 in the form 10b5-1 | −5,000 | $14.90 | $74,500 | 1,736 | D |
| 2024-05-01 | Sale : show line 4 in the form 10b5-1 | −100 | $15.63 | $1,563 | 1,636 | D |
| Open-market sales · 20,000 sh · avg $14.13 · $282,577 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-05-01 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) | −20,000 | 281,652 | D |
Loading xslF345X05/form4.xml…